TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01071031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-v (Low Dose)
Description: Low Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences) with water for injection or adjuvant~Administration: A single subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-v (Low Dose)
Description: Low Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences) with water for injection or adjuvant~Administration: A single subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-v (High Dose)
Description: High Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences with water for injection or adjuvant~Administration: A single subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-v (High Dose)
Description: High Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences with water for injection or adjuvant~Administration: A single subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HIV-v (Control)
Description: Adjuvant only or Water for injection only~Administration: A single subcutaneous injection
Study: NCT00697801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 low dose
Description: a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 high dose
Description: a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered by nebulization twice daily for 6 weeks
Study: NCT03886649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The only dose level 1 (DL1) is 60 mg copanlisib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The starting dose is dose level 1 (DL1): 600 mg venetoclax.
Study: NCT02463838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Support Intervention
Description: Case management and care coordination intervention delivered in person to SFHP members who are frequent users of emergency department and inpatient hospital services.
Study: NCT03371329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: bone marrow derived cultured MSC (mesenchymal stem cell)
Study: NCT00647205

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: QuantiFERON TB Gold In-Tube

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: QuantiFERON TB Gold In-Tube

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: QuantiFERON TB Gold In-Tube

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: QuantiFERON TB Gold In-Tube

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: QuantiFERON TB Gold In-Tube

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: T-SPOT.TB®

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: T-SPOT.TB®

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: T-SPOT.TB®

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: T-SPOT.TB®

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: T-SPOT.TB®

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: T-SPOT.TB®
Study: NCT01909232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
Description: The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the active group, magnetic power output will be delivered to the subject through the coils.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
Description: The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
Study: NCT02577484

Intervention type: DEVICE
Intervention: RXi System
Description: Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.~Measurement of FFR requires simultaneously monitoring the blood pressures proximal and distal to a lesion. The RXi system includes a single use catheter (Navvus) with a pressure sensor for acquisition of the distal pressure. The proximal pressure is acquired by the guide catheter via an interface to the hospital hemodynamic monitor.~The Navvus catheter interfaces to the RXi system console which includes embedded software, a user interface touch screen and associated electronics.
Study: NCT00400738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir, lopinavir, ritonavir
Description: arm 1 = LPV/RTV 400/100 mg BID + SQV 1000 mg BID arm 2 = LPV/RTV 400/100 mg BID + SQV 600 mg BID arm 3 = LPV/RTV 266/66 mg BID + SQV 1000 mg BID arm 4 = LPV/RTV 266/66 mg BID + SQV 600 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir, lopinavir, ritonavir
Description: arm 1 = LPV/RTV 400/100 mg BID + SQV 1000 mg BID arm 2 = LPV/RTV 400/100 mg BID + SQV 600 mg BID arm 3 = LPV/RTV 266/66 mg BID + SQV 1000 mg BID arm 4 = LPV/RTV 266/66 mg BID + SQV 600 mg BID
Study: NCT02577484

Intervention type: DEVICE
Intervention: Pressure Wire
Description: Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.
Study: NCT01178762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
Study: NCT02377362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLWL-01, Part A
Description: Capsules administered orally, in 2 out of 3 periods

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Part A
Description: Capsules administered orally in 1 out of 3 periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLWL-01, Part B
Description: Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Part B
Description: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLWL-01, Part C
Description: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Part C
Description: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
Study: NCT00409058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Online Problem Solving
Description: We will test the following hypotheses: 1) Children with TBI receiving TOPS will have fewer behavior problems, greater social competence, and better functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 2) Caregivers of children receiving TOPS will report less depression and psychological distress, less parent-child conflict, and better family functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 3) Social resources will moderate treatment efficacy, such that children with limited social and economic resources will show greater improvements in the more comprehensive TOPS intervention. We hypothesize better teen problem solving and communication skills, fewer teen emotional/behavioral problems, less parental burden and distress, and less parent-teen conflict at follow-up among the TOPS group compared to the IRC group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Online Problem Solving
Description: We will test the following hypotheses: 1) Children with TBI receiving TOPS will have fewer behavior problems, greater social competence, and better functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 2) Caregivers of children receiving TOPS will report less depression and psychological distress, less parent-child conflict, and better family functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 3) Social resources will moderate treatment efficacy, such that children with limited social and economic resources will show greater improvements in the more comprehensive TOPS intervention. We hypothesize better teen problem solving and communication skills, fewer teen emotional/behavioral problems, less parental burden and distress, and less parent-teen conflict at follow-up among the TOPS group compared to the IRC group.
Study: NCT01819038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous renal replacement therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous renal replacement therapy
Study: NCT01482273

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CDT+US group
Description: CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CDT-US group
Description: CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
Study: NCT01238354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: With friend

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Without friend
Study: NCT02280070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory test
Description: Leukocyte, neutrophil (ANC ：stab + seg), hemoglobin, platlet, albumin, total birrilubin, AST, ALT, LDH, Creatinine, Na, K, CRP, fast blood sugar

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory test
Description: Leukocyte, neutrophil (ANC ：stab + seg), hemoglobin, platlet, albumin, total birrilubin, AST, ALT, LDH, Creatinine, Na, K, CRP, fast blood sugar
Study: NCT01819038

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous renal replacement therapy
Study: NCT01723436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothetical scenarios and related decisions
Description: Surrogates are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothetical scenarios and related decisions
Description: Surrogates are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothetical scenarios and related decisions
Description: Surrogates are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
Study: NCT01003015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY73-4506
Description: 160 mg BAY73-4506
Study: NCT03787875

Intervention type: PROCEDURE
Intervention: periodontal treatment
Description: In the study group, periodontal scaling and root planning treatment of the 4 quadrants was performed for two consecutive weeks without the use of antiseptics or antibiotics, and the patients were instructed in oral hygiene, including both brushing techniques and proximal hygiene.
Study: NCT01638624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol :Propofol is an anesthetic agent, has structure similar to that of known such as alfa tocopherol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01513642

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breath Stacking
Description: To perform the BS maneuver, a silicone mask containing a one-way valve was attached to the patient's face. Once the mask was adjusted to allow only inspiration (the expiratory branch remained occluded), the patient was asked to make successive inspiratory efforts during 20 seconds.
Study: NCT02896894

Intervention type: OTHER
Group type: OTHER
Intervention: Big White Wall (BWW)
Description: The BWW is an internet-based intervention that incorporates several elements of mental health care that have been shown to be effective, in a virtual environment that provides anonymity (see www.bigwhitewall.com). The on-line portal gives users access to self-assessment tools to track symptoms for a wide range of conditions over time, educational materials, a social network that allows communication between people who may have similar problems, and access to on-line courses. The service is monitored at all times by Wall Guides to ensure that users are responded to and that the content posted is appropriate and safe.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Big White Wall (BWW)
Description: The BWW is an internet-based intervention that incorporates several elements of mental health care that have been shown to be effective, in a virtual environment that provides anonymity (see www.bigwhitewall.com). The on-line portal gives users access to self-assessment tools to track symptoms for a wide range of conditions over time, educational materials, a social network that allows communication between people who may have similar problems, and access to on-line courses. The service is monitored at all times by Wall Guides to ensure that users are responded to and that the content posted is appropriate and safe.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Big White Wall (BWW)
Description: The BWW is an internet-based intervention that incorporates several elements of mental health care that have been shown to be effective, in a virtual environment that provides anonymity (see www.bigwhitewall.com). The on-line portal gives users access to self-assessment tools to track symptoms for a wide range of conditions over time, educational materials, a social network that allows communication between people who may have similar problems, and access to on-line courses. The service is monitored at all times by Wall Guides to ensure that users are responded to and that the content posted is appropriate and safe.
Study: NCT02916719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI examination after the neo-adjuvant radiotherapy, but before the surgical treatment
Study: NCT03315507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB1046 Subcutaneous Injection
Description: Eight weekly doses of PB1046.
Study: NCT02755363

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: osteopathic manual therapy
Description: * suboccipital decompression - atlanto-occipital joint relaxation technique.~* deep cervical fascia release - the technique aims to improve mobility of the first and second ribs during expiration and to relaxation of the vagus and phrenic nerve course area.~* thoracic lymphatic pump with activation is designed to reduce the tension of mediastinal structures, improve lymphatic flow, and thus reduce the breathing resistance.~* stretching the diaphragm in order to relax and reduce adhesion within the fascial system between the diaphragm and abdominal organs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: * manual mobilization techniques of the slides in the shoulder joint toward the front, rear and bottom.~* manual techniques to increase range of motion in the shoulder joints using the patient's breathing manoeuvres.
Study: NCT01805362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomization that determine the time of treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomization that determine the time of treatment
Study: NCT04061408

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic radiotherapy(FSRT)
Description: 3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
Study: NCT00759837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Study: NCT03098290

Intervention type: PROCEDURE
Intervention: Catheter-based endovascular revascularization
Description: (e.g. PTA-alone, Bare-Metal or Drug-Eluting-Stent, Covered Stent, Atherectomy, Mechanical Thrombectomy, Scoring Ballon, Cutting Ballon)
Study: NCT02280070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical history and physical examination
Description: medical history and physical examination

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical history and physical examination
Description: medical history and physical examination

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BW and height
Description: Body weight (kg) and height (cm)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BW and height
Description: Body weight (kg) and height (cm)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Performance status
Description: ECOG performance status, 0: Fully active, able to carry on all pre-disease performance without restriction, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work, 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours, 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5: Dead

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Performance status
Description: ECOG performance status, 0: Fully active, able to carry on all pre-disease performance without restriction, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work, 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours, 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5: Dead

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Creatinine clearance
Description: Creatinine clearance (CCr, mL/min) was estimated by Cockcroft \& Gault method using serum creatinine (mg/dL), age and body weight (kg).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Creatinine clearance
Description: Creatinine clearance (CCr, mL/min) was estimated by Cockcroft \& Gault method using serum creatinine (mg/dL), age and body weight (kg).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomarker
Description: Carcinoembryonic antigen and carbohydrate antigen 19-9

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomarker
Description: Carcinoembryonic antigen and carbohydrate antigen 19-9

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Contrasting CT
Description: Computed tomography

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Contrasting CT
Description: Computed tomography
Study: NCT03098290

Intervention type: PROCEDURE
Intervention: Catheter-based endovascular revascularization
Description: (e.g. PTA-alone, Bare-Metal or Drug-Eluting-Stent, Covered Stent, Atherectomy, Mechanical Thrombectomy, Scoring Ballon, Cutting Ballon)

Intervention type: PROCEDURE
Intervention: Catheter-based endovascular revascularization
Description: (e.g. PTA-alone, Bare-Metal or Drug-Eluting-Stent, Covered Stent, Atherectomy, Mechanical Thrombectomy, Scoring Ballon, Cutting Ballon)
Study: NCT02280070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adverse event
Description: AE was evaluated using Common Terminology Criteria for Adverse Events (CTCAE v4.0).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adverse event
Description: AE was evaluated using Common Terminology Criteria for Adverse Events (CTCAE v4.0).
Study: NCT03098290

Intervention type: PROCEDURE
Intervention: Bypass-Surgery
Description: Venous or alloplastic or comparable Bypass

Intervention type: PROCEDURE
Intervention: Bypass-Surgery
Description: Venous or alloplastic or comparable Bypass

Intervention type: PROCEDURE
Intervention: Bypass-Surgery
Description: Venous or alloplastic or comparable Bypass

Intervention type: PROCEDURE
Intervention: Endarterectomy
Description: Endarterectomy, Patchplasty

Intervention type: PROCEDURE
Intervention: Endarterectomy
Description: Endarterectomy, Patchplasty

Intervention type: PROCEDURE
Intervention: Endarterectomy
Description: Endarterectomy, Patchplasty
Study: NCT02280070

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HBs antigen and HCV antibody
Description: check for exclusion criteria

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HBs antigen and HCV antibody
Description: check for exclusion criteria
Study: NCT00422201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Singe dose
Study: NCT01234532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Lumpectomy or mastectomy will be performed follwoing day 29 of study therapy
Study: NCT02041676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual surveillance
Description: Usual surveillance of the non invasive ventilation without chest physiotherapy.
Study: NCT03152149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium & olodaterol
Description: Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months